You are unable to edit this page, please log in to edit .
This page seems to be incomplete!
22%
Please help us to improve this report - add or edit content. Top editors receive sponsorship revenues that this report may get. (see all pages having same badge)

Market Potential of Generic Drugs in the US

Estimates show that the Generic drugs will account for nearly $350 Billion in revenue by year 2015 with an expected CAGR of 12% over next five years.

  • Page views 3216 views
  • Page contributors 3 Editors
  • Page update date Updated about 1 year ago

Definition / Scope

A generic drug is identical -- or bio-equivalent -- to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use”

Generic drugs need to have same high quality, strength, purity stability as that of branded drugs and generic versions of the branded drugs only come to market when the patent of the branded drugs expire.

Pharmaceutical companies which focus on Generic forms of a patented drug have to file for approval with USFDA.    

These filing termed as Abbreviated New Drug Approval (ANDA) are reviewed and validated by the USFDA allowing the manufacturer to market the generic forms.   

The cost involved in developing a generic drug is very low considering the shortened development process compared to the innovator. Additionally, the risks and the marketing costs are also lower due to the awareness of the innovator drug for a disease segment in the market.   ''Standards to be met for ANDA Approval by USFDA[1]

  • Should contain the same ingredient as that of Innovator drug
  • Should be a bioequivalent
  • Should be identical in strength, dosage form and route of administration
  • Should have the same use indications 
  • Should meet the same batch requirements for identity, strength, purity and quality
  • Should be manufactured under the same strict standards of FDAs Good Manufacturing Practices

Market Overview

  • With nearly 8 out of 10 prescriptions filled in the US for generic drugs, the use of generic drugs is expected to grow over the next few years.
  • Estimates show that the Generic drugs will account for nearly $350 Billion in revenue by year 2015 with an expected CAGR of 12% over next five years.
  • The big difference between generic and branded drugs is the price; with the generic drugs costing 80 to 85 percent lower than the branded product.
  • According to the Congressional Budget Office, generic drugs save consumers an estimated $8 to $10 billion a year at retail pharmacies. Even more billions are saved when hospitals use generics.
  • A healthy growth potential is predicted for US Generics market in various therapeutic segments, such as oncology, respiratory, thyroid, ulcers and cholesterol disorders in the coming years.
  • Growth in the aforementioned segments will be the result of patent expirations of major drugs in the next few years.
  • The support from the US government in the form of approvals and incentives, will also act as a catalyst for future growth in the generic domain.
  • The US generic drug market is expected to grow at a high CAGR of 12% and comprises of 80% of the US Pharmaceutical market
  • Driven by strong demand, favorable government policies, preference of cost effective medication and an aging population to serve
  • Highly attractive market with the presence of global players including large innovator companies
  • Prominent but low market risks which would not prove as an immediate threat to the industry
  • Provides opportunities to companies to apply innovative strategies to gain entry as well as increase its market presence

Key Metrics

Metrics Value Explanation
Base Year 2016 Researched through internet


Market Risks

The proposed USFDA regulation wherein the generic companies have to update their product labels based on the safety risks identified through post market surveillance is a key risk to manufacturers. This regulation would increase the risks in terms of the additional costs related to regulatory adherence, litigation risks and eventually lead to the increase in the price of the drugs.

Additionally, with the increase in the number of international players that have entered in to the US generic market, the product margins are ever shrinking; resulting in fierce competition. Manufacturers from India & China have a higher price advantage due to lower costs of raw materials and labor.

In parallel, the USFDA has become stringent in implementing regulatory guidelines for the manufacturing of drugs with frequent inspections at sites. Though this would lead high quality of drugs but might also act as a deterrent for entry of new players and also can lead to suspension or closure of manufacturing facilities; reducing of supply and affecting the attractiveness of the market.

The high number of drugs going off patent by year 2020 is an opportunity to the industry, but it also poses a threat as the generic drug manufacturers not have a strong pipeline in long term. With low pipeline of innovator drugs in future, the generic drug market may move towards stagnancy.

Finally, the global pharmaceutical industry is witnessing consolidation of large players through mergers and acquisitions, leading to a very few players controlling the entire generic market. It is speculated that in coming years there will be couple of big pharma players which would control the majority of the US pharmaceutical market as well as generics.

Top Market Opportunities

First to file exclusivity – The USFDA provides approval to a generic manufacturer to market their drug exclusively for 180 days through its First to file exclusivity policy. In such a scenario, for a particular drug there would be only two suppliers; one being the innovator and the second is the generic company first to file. This exclusivity also prevents other generic manufacturers thereby providing advantage to the first filed generic firm. One of the most relevant examples is of Lipitor for which Ranbaxy was awarded the exclusivity by USFDA

Quality deliverables – As previously mentioned the USFDA is stringent in its regulatory guidelines; pharmaceutical companies should have robust quality systems and provide quality deliverables to win a higher margin of revenue in the market.

Expansion of manufacturing base to cost effective countries – With high manufacturing costs in US, generic drug manufacturers should expand their manufacturing base to countries such as India, China and other South East Asian countries which provide high cost advantage. Such a move would also help them in supplying their drugs at a competitive cost compared to the generic manufacturers from those countries.

Market Drivers

The US Generic drug market is witnessing growth due to the key factors such as –

  • Demand for Cost Effective medication – The therapeutic equivalency and lower cost of generic drugs are proving to be cost effective medication.
  • Rising Healthcare expenses – The rising healthcare expenditure is forcing government and insurance companies to identify ways to control healthcare costs. Thus creating increased demand for generic drugs.
  • Increased aging population – Globally there is an increase in aging population which would lead to the higher drug utilization and hence an increased focus on generics. According to GlobalData, the elderly will make up to 22 percent of the population of US by 2020 which is around 19 percent currently.
  • Patent expiration of blockbuster drugs – A major number of patented drugs are coming off patent by 2020, leading to increase in the opportunity for generics. Biosimilar, first-to-file and branded generics are the key focus areas.
  • Enhanced government support – The introduction of the Affordable Care Act would increase the numbers for newly insured and add those who will sign up for accessible insurance plans. Thus boosting the healthcare spending of US and increase the revenue of generic firms. Also the USFDA is proposing to charge a fee for ANDAs under the Generic Drug User Fee Act which might lead to faster review of applications and increased availability of the drugs in the market.
  • Competitive Environment - Increase in competition in the generic drug market is due companies from Indian, China, and Eastern Europe as manufacturers from these countries have a high cost advantage creating a highly competitive environment

List of top innovator drugs going off patent by 2020[2]

Brand

Active Pharmaceutical Ingredient

Manufacturer

Expected Patent Expiry

Androgel

Testosterone

Solvay

2016

Avodart

Dutasteride

Glaxo Smith Kline

2015

Benicar

Olmesartan

Daiichi Sankyo

2016

Benicar HCT

Olmesartan Hydrocholorothiazide

Daiichi Sankyo

2016

Crestor

Rosuvastatin

AstraZeneca

2016

Gleevac

Imatinib

Novartis

2015

Lovaza

Omega 3 acid esters

Glaxo Smith Kline

2015

Namenda

Memantine

Forest Laboratories

2015

Reyataz

Atazanavir

Bristol-Myer-Squibb

2017

Seroquel XR

Quetiapine ER

Astra Zeneca

2017

Strattera

Atomoxetine

Lilly

2017

Viagra

Sildenafil

Pfizer

2020

Zetia

Ezetimibe

Merck

2016


Other Key Market Trends

The sector has a promising CAGR estimate of 12% in next 5 years which is attracting leading pharmaceutical companies of US including branded drug manufacturers, generic drug companies and other players from countries such as India, China and Eastern Europe.

Some of the leading generic drug manufacturers include Teva Pharmaceuticals, Sandoz, Mylan, Actavis, Aspen Pharmacare, Hospira, Diachi Sankyo, Sanofi, Sun Pharma & Lupin. Other key international players include Dr Reddy Laboratories, Glenmark, Taro Pharma & Adcock Ingram etc.

Top 10 Generic Drugs Prescribed in 2014[3]

Name of the generic drug

No of Prescriptions

HYCD/APAP

123,365,902

LISINOPRIL

103,090,396

LEVOTHYROXINE SOD

95,170,627

ATORVASTATIN CA

76,987,591

AMLODIPINE BESY

76,404,927

SIMVASTATIN

73,468,752

OMEPRAZOLE (RX)

73,161,061

METFORMIN HCL

61,162,279

AMOXICILLIN

53,807,690

HYDROCHLOROTHIAZIDE

49,555,088


Market Outlook

The outlook of the US Generic market is very positive with good signs of growth contributed by factors such as government policies, higher number of innovator drugs going off patent, and growing demand of cost effective medication.

At the same time, the industry has to be vigil and should map the changes in the regulatory guidelines from which could have major impact in their manufacturing costs and filling of ANDAs in future. Increased presence of manufacturers from countries like India, China and others that provide cost effective drugs would act as a threat to US based companies

Overall, the industry would flourish in upcoming years with the positive factors driving the market size and revenues but the sector would have to sail through the ever changing regulatory environment and deliver quality products in a cost effectively.

References

  1. USFDA
  2. International Journal of Pharmacy & Pharmaceutical Sciences
  3. IMS Health

Further Reading


Share this page: